Skip to content

Prime Medicine PRME Property, plant and equipment at cost

Property, plant and equipment at cost at other companies

Precigen logo
PrecigenPGEN

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$50.7M+3.3%
Net income-$49.1M+5.3%
EPS (diluted)-$0.28+30.0%

Balance sheet

See full
Cash & equivalents$77.8M-26.6%
Total debt$114.5M-5.5%
Total equity$76.7M-28.3%
Total assets$294.7M-10.2%

Cash flow

See full
Operating cash flow-$42.7M+12.6%
CapEx$214.0K-91.2%
Free cash flow-$42.9M+16.3%

Valuation

See full
Market cap$574.36M+111%
Enterprise value$611.08M+113%
P/S124×+6.3×

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%

Returns & leverage

See full
Return on equity-216.1%+1,519pp
Debt / equity1.5×+0.4×
Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's property, plant and equipment at cost.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prime Medicine's property, plant and equipment at cost?
Prime Medicine (PRME) reported property, plant and equipment at cost of $41.11M in Q1 2026.
How has Prime Medicine's property, plant and equipment at cost changed year-over-year?
Prime Medicine's property, plant and equipment at cost increased by 2.1% year-over-year, from $40.25M to $41.11M.
What is the long-term trend for Prime Medicine's property, plant and equipment at cost?
Over 4 years (2021 to 2025), Prime Medicine's property, plant and equipment at cost has grown at a 64.9% compound annual growth rate (CAGR), from $5.54M to $41.01M.